<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1664">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02129400</url>
  </required_header>
  <id_info>
    <org_study_id>2014-000973-38</org_study_id>
    <nct_id>NCT02129400</nct_id>
  </id_info>
  <brief_title>Influence on Erythropoetin-level by Xenon</brief_title>
  <acronym>XEPO</acronym>
  <official_title>Xenon-inhalation: Elimination of Xenon and Its Effect on Erythropoetin Levels in Blood of Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the effect of xenon-inhalation on
      erythropoetin-level in blood of healthy volunteers and to determine the efficient time of
      inhalation.

      Hypothesis: Xenon-inhalation enhances erythropoetin-levels in blood
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xenon-gas is an approved anesthetic by the EMEA and is used for a balanced anesthesia in
      combination with opioids for adults with a american society of anesthesiology classification
      ASA ≤ III. Several clinical and pre-clinical studies have shown a positive effect of xenon
      on several organ functions such as in brain, kidneys and heart. In two studies, an enhanced
      expression of hypoxia inducible factor-1α (HIF-1α) could be shown in animal kidneys and
      kidney cells. Interestingly, HIF-1α leads to an enhanced formation of erythropoetin (EPO).
      This might result in an enhanced oxygen transport capacity and an enhanced oxygen-level
      after xenon-treatment.

      Aim of the project is to analyze the effect of xenon-inhalation on circulating
      erythropoetin-level in blood of healthy volunteers in a randomized controlled pilot study.
      Besides, other positive stimulating factors for erythropoiesis (such as HIFa stabilizing
      factors) and growth factors (such as fibroblast growth factors (FGFs), hepatocyte growth
      factor (HGF), mechano growth factors (MGFs), platelet-derived growth factors (PDGFs),
      vascular endothelial growth factors (VEGFs)) shall be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline in erythropoetin-level in blood of healthy volunteers up to 216 hrs after the first of three xenon applications in total</measure>
    <time_frame>up to 216 hrs after first xenon-application</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in erythropoetin-level in blood of healthy volunteers up to 216 hrs after the first of three xenon applications in total.
Timepoints of measurement:
Before each inhalation, Directly after the first inhalation, 2 hrs after the first inhalation, 4 hrs after the first inhalation, 8 hrs after the first inhalation, 22-24 hrs after each inhalation, 46-48 hrs after each inhalation, 70-72 hrs after the last inhalation, 94-96 hrs after the last inhalation, 118-120 hrs after the last inhalation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First-order elimination of xenon after xenon-inhalation in blood and exhalation air by mass-spectroscopy</measure>
    <time_frame>up to 216 hrs after the first xenon-application</time_frame>
    <safety_issue>No</safety_issue>
    <description>Timepoints of measurement:
Before each inhalation, Directly after the first inhalation, 2 hrs after the first inhalation, 4 hrs after the first inhalation, 8 hrs after the first inhalation, 22-24 hrs after each inhalation, 46-48 hrs after each inhalation, 70-72 hrs after the last inhalation, 94-96 hrs after the last inhalation, 118-120 hrs after the last inhalation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determination of hemodynamic parameters (HF, RR, EKG, SpO2, rSO2, tSO2)</measure>
    <time_frame>up to 216 hrs after the first xenon-application</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time points of measurement:
Before each inhalation, Directly after the first inhalation, 2 hrs after the first inhalation, 4 hrs after the first inhalation, 8 hrs after the first inhalation, 22-24 hrs after each inhalation, 46-48 hrs after each inhalation, 70-72 hrs after the last inhalation, 94-96 hrs after the last inhalation, 118-120 hrs after the last inhalation</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory parameters: Inflammation (procalcitonin, IL-6, IL-10, leukocytes, thrombocytes), growth factors (HIF1α, FGFs, HGF, MGFs, PDGF, VEGF, IL-8, VEGF, MIF, SDF-1a)</measure>
    <time_frame>up to 216 hrs after the first xenon-application</time_frame>
    <safety_issue>No</safety_issue>
    <description>Timepoints of measurement:
Before each inhalation, Directly after the first inhalation, 2 hrs after the first inhalation, 4 hrs after the first inhalation, 8 hrs after the first inhalation, 22-24 hrs after each inhalation, 46-48 hrs after each inhalation, 70-72 hrs after the last inhalation, 94-96 hrs after the last inhalation, 118-120 hrs after the last inhalation</description>
  </other_outcome>
  <other_outcome>
    <measure>Oxidative stress: total oxidative capacity, peroxide activity, LDL antibodies: antibody against oxided LDL, e.g. MDA-LDL IgM, oLAb (IgG)</measure>
    <time_frame>up to 216 hrs after the first xenon-application</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time points of measurement:
Before each inhalation, Directly after the first inhalation, 2 hrs after the first inhalation, 4 hrs after the first inhalation, 8 hrs after the first inhalation, 22-24 hrs after each inhalation, 46-48 hrs after each inhalation, 70-72 hrs after the last inhalation, 94-96 hrs after the last inhalation, 118-120 hrs after the last inhalation</description>
  </other_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>10min Xenon 15%, FiO2 75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 minutes of 15 % xenon-inhalation (with 75 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10min Xenon 30%, FiO2 60%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 minutes of 30 % xenon-inhalation (with 60 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30min Xenon 15%, FiO2 75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 minutes of 15 % xenon-inhalation (with 75 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30min Xenon 30%, FiO2 60%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 minutes of 30 % xenon-inhalation (with 60 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45min Xenon 15%, FiO2 75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 minutes of 15 % xenon-inhalation (with 75 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45min Xenon 30%, FiO2 60%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 minutes of 30 % xenon-inhalation (with 60 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90min Xenon 15%, FiO2 75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 minutes of 15 % xenon-inhalation (with 75 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90min Xenon 30%, FiO2 60%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 minutes of 30 % xenon-inhalation (with 60 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10min air medicinalis, FiO2 75%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 minutes of air medicinalis (with 75 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10min air medicinalis, FiO2 60%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 minutes of air medicinalis inhalation (with 60 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30min air medicinalis, FiO2 75%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 minutes of air medicinalis inhalation (with 75 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30min air medicinalis, FiO2 60%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 minutes of air medicinalis inhalation (with 60 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45min air medicinalis, FiO2 75%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>45 minutes of air medicinalis inhalation (with 75 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45min air medicinalis, FiO2 60%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>45 minutes of air medicinalis inhalation (with 60 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90min air medicinalis, FiO2 75%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>90 minutes of air medicinalis inhalation (with 75 % FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90min air medicinalis, FiO2 60%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>90 minutes of air medicinalis inhalation (with 60 % FiO2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenon pro Anaesthesia 100 % (V/V)</intervention_name>
    <description>Xenon-gas inhalation of indicated concentrations during indicated time</description>
    <arm_group_label>10min Xenon 15%, FiO2 75%</arm_group_label>
    <arm_group_label>10min Xenon 30%, FiO2 60%</arm_group_label>
    <arm_group_label>30min Xenon 15%, FiO2 75%</arm_group_label>
    <arm_group_label>30min Xenon 30%, FiO2 60%</arm_group_label>
    <arm_group_label>45min Xenon 15%, FiO2 75%</arm_group_label>
    <arm_group_label>45min Xenon 30%, FiO2 60%</arm_group_label>
    <arm_group_label>90min Xenon 15%, FiO2 75%</arm_group_label>
    <arm_group_label>90min Xenon 30%, FiO2 60%</arm_group_label>
    <other_name>licence number: 56582.00.00</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aer medicinalis Linde 100%</intervention_name>
    <arm_group_label>10min air medicinalis, FiO2 75%</arm_group_label>
    <arm_group_label>10min air medicinalis, FiO2 60%</arm_group_label>
    <arm_group_label>30min air medicinalis, FiO2 75%</arm_group_label>
    <arm_group_label>30min air medicinalis, FiO2 60%</arm_group_label>
    <arm_group_label>45min air medicinalis, FiO2 75%</arm_group_label>
    <arm_group_label>45min air medicinalis, FiO2 60%</arm_group_label>
    <arm_group_label>90min air medicinalis, FiO2 75%</arm_group_label>
    <arm_group_label>90min air medicinalis, FiO2 60%</arm_group_label>
    <other_name>Pharmakotherapeutic group: medical gas</other_name>
    <other_name>Licence number: 68885.00.00</other_name>
    <other_name>ATC-Code: V03AN05</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects

          -  Age: &gt; 18 years

          -  legally competent to sign

          -  without any known medical condition or medication prescribed at the University
             Hospital RWTH Aachen, Germany

          -  Persons that are able and willing to understand and follow the instructions of the
             study personnel

          -  Signed informed consent

        Exclusion Criteria:

          -  Smoker, alcoholic or person who regularly consumes drugs or medication

          -  Persons with a medical condition that is contraindicated with the planned treatment

          -  Known hypersensitivity against xenon

          -  Persons not legally competent to sign

          -  Simultaneous participation at any other trial

          -  Blood-loss due to trauma during the period of the study or 2 months previous

          -  Blood donation during the period of the study or 2 months previous
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Rossaint, Prof. M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital RWTH Aachen, Department for Anesthesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rolf Rossaint, Prof. M.D.</last_name>
    <phone>+49 241 80 36707</phone>
    <email>rrossaint@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Sudhoff, PhD</last_name>
    <phone>+49 241 80 37429</phone>
    <email>asudhoff@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital RWTH Aachen, Department for Anesthesia</name>
      <address>
        <city>Aachen</city>
        <state>North-Rhine Westfalia</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rolf Rossaint, Prof. M.D.</last_name>
      <phone>+49 241 80 36707</phone>
      <email>rrossaint@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Marc Coburn, Prof. M.D.</last_name>
      <phone>+49 241 80 35394</phone>
      <email>mcoburn@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Rolf Rossaint, Prof. M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Coburn, Prof. M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xenon-inhalation</keyword>
  <keyword>Erythropoetin</keyword>
  <keyword>Pharmakokinetic</keyword>
  <keyword>Pharmacodynamic</keyword>
  <keyword>Hemodynamic parameters</keyword>
  <keyword>Inflammatory parameters</keyword>
  <keyword>Growth factors</keyword>
  <keyword>Oxidative stress parameters</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Xenon</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
